Logo

Adaptive Biotechnologies: Mark Adams, Nancy Hill

Jan 27, 2021

Adaptive Biotechnologies has appointed Mark Adams as chief operating officer effective Jan. 25, 2021. Adams, 53, joined Adaptive in April 2020 as chief technical officer.  

Adams holds a PhD in cell biology from Baylor College of Medicine and completed his postdoc in computational biology at Boston University.

On Jan. 21, 2021, Adaptive and Nancy Hill, the firm's executive VP of operations and program management, agreed that her tenure will be terminated, effective March 2, 2021. Hill's termination is not the result of any material disagreement with the company regarding its operations, policies, or practices, Adaptive said in a filing with the US Securities and Exchange Commission.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.